Clinical Trials Browser

Recruiting × Sarcoma × pembrolizumab × Clear all

Mesothelioma, Sarcoma, Cholangiocarcinoma, Neurofibrosarcoma

NCT07410676 2026-02-18

EBNK-ST-001

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Bronchogenic, Disease, Esophageal Neoplasms, Glioblastoma, Kidney Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms

NCT04332874 2026-01-30

A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

Phase 2 Recruiting

30 enrolled

Sarcoma

Sarcoma, Dermatofibrosarcoma, Sarcoma, Alveolar Soft Part, Histiocytoma, Malignant Fibrous

NCT07089992 2025-12-16

A Study of Pembrolizumab in People With Ultra-Rare Sarcomas

Phase 2 Recruiting

32 enrolled

Sarcoma

Liposarcoma, Sarcoma, Perivascular Epithelioid Cell Neoplasms

NCT04370587 2025-10-08

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Phase 1/2 Recruiting

30 enrolled

DermatologicHead & NeckSarcoma

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Melanoma, Sarcoma

NCT06789172 2025-09-05

INVOKE

Phase 1 Recruiting

166 enrolled

GastrointestinalHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Liposarcoma, Sarcoma, Colorectal Neoplasms, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous, Solitary Fibrous Tumors

NCT05679921 2025-07-16

Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma

Phase 2 Recruiting

116 enrolled

Sarcoma

NCT06113809 2025-06-03

Palbociclib and Pembrolizumab in Sarcoma

Phase 1 Recruiting

8 enrolled

Sarcoma

NCT05824975 2024-11-25

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Phase 1/2 Recruiting

358 enrolled

DermatologicGastrointestinalGenitourinarySarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

NCT04541108 2024-04-18

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Phase EARLY_PHASE1 Recruiting

15 enrolled

DermatologicHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lymphoma, Melanoma, Sarcoma

NCT05961761 2023-07-27

PROPANE

Phase 2 Recruiting

80 enrolled

Sarcoma

Hemangiosarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

Clinical Trials

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

EBNK-ST-001

A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

A Study of Pembrolizumab in People With Ultra-Rare Sarcomas

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

INVOKE

Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma

Palbociclib and Pembrolizumab in Sarcoma

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

PROPANE